NEW YORK – China's Zion Pharma on Tuesday said that it had dosed the first patient in the US with its investigational HER2-targeting drug, ZN-A-1041. The agent is designed to cross the blood-brain barrier, ultimately treating brain metastases in patients with advanced breast cancer.